Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 6Lymphoid 1

Conditions

Recurrence 5Lymphoma, Extranodal NK-T-Cell 5Lymphoma 5Hodgkin Disease 5Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma, T-Cell, Peripheral 2Solid Tumor 1Neoplasms 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1Immunoblastic Lymphadenopathy 1Carcinoma, Non-Small-Cell Lung 1B-cell Malignancies 1

Interventions

tislelizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Solid Tumor × tislelizumab × Lymphoid × Clear all
NCT05833984 2023-04-27

Safety and Efficacy of IMM01 Plus Tislelizumab in Patients With Advanced Solid Tumors and Lymphomas

ImmuneOnco Biopharmaceuticals (Shanghai) Inc.

Phase 1/2 Unknown
309 enrolled
LymphoidOther solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡